• Eisai Inc., of Woodcliff Lake, N.J., said the FDA granted orphan drug designation to E7777 for cutaneous T-cell lymphoma. E7777 is designed to have an improved purity profile and manufacturing process. Read More
• Transcept Pharmaceuticals Inc., of Point Richmond, Calif., recorded about $500,000 in royalty revenue from sales of insomnia drug Intermezzo (low-dose zolpidem) generated by partner Purdue Pharma LP, of Stamford, Conn. Read More
• Infinity Pharmaceuticals Inc., of Cambridge, Mass., expects to begin a Phase III trial of IPI-145 in chronic lymphocytic leukemia and small lymphocytic lymphoma in the fourth quarter. Read More
• Ampliphi Biosciences Corp., of Richmond, Va., presented data at the Biennial Evergreen International Phage meeting in Olympia, Wash., relating to its use of bacteriophages in the treatment of Pseudomonas aeruginosa, the major cause of lung infections in cystic fibrosis (CF) patients. Read More
LONDON – A new understanding of the molecular control of angiogenesis – the process by which new blood vessels grow – could lead to new therapies aimed at blocking tumor growth. Read More
Lakewood-Amedex might sound like a picturesque stop on a rail line or a high-end entertainment venue, but the privately held biotech is all business. Read More
While some universities may still be spinning their wheels in the red ink spewing from the Bayh-Dole Act, Emory University has built a vehicle it can use to drive promising science across the valley of death into full-scale drug development. Read More
As expected, New York-based Keryx Biopharmaceuticals Inc. submitted a new drug application (NDA) for Zerenex (ferric citrate coordination complex) in the initial indication of treating elevated serum phosphorus levels, or hyperphosphatemia, in patients with chronic kidney disease (CKD) on dialysis. Read More
Drug development accelerator Biomotiv LLC added $25 million to boost its capital commitment to $46 million, with Nationwide Mutual Insurance Co. and several individual investors joining founding investors University Hospitals of Cleveland and the Harrington Family. Nationwide, based in Cleveland, will appoint a representative to the company's board of managers. Read More
• Organovo Holdings Inc., of San Diego, said it closed its public offering of 9 million shares, plus an additional 1.35 million shares in overallotments, priced at $4.50 each. Read More
